Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by stockman6767on Nov 30, 2016 5:24pm
184 Views
Post# 25536688

RE:RE:RE:Bloom Burton and Co.: Hold rating and $2.00 target for PLI

RE:RE:RE:Bloom Burton and Co.: Hold rating and $2.00 target for PLIBepando, you wrote: "You joined this BB yesterday so you could post this piece of Shiiiittt today. You obviously are part of the BB team who's only purpose is to support their shorting clients to drive the PLI share price lower and keep it down. Your role is clearly described in the Wyckoff article."

You are probably right about the intentions of WalkingonNails, but you are probably too tough on him as I describe below.

You also wrote: "
Anyone who gives any credibility to BB in any capacity they present are fools -- that's why PLI didn't respond; they are no fools"

Here, I totally disagree with you. The Bloom Burton report may not be what we want to hear, but they are valid questions that I am sure have very valid reason on the part of PLI. So in my opinion, the better response by PLI would not be to ignire these issues and leave them lingering in some minds, Rather the information that would explain should be released perhaps through Fred informally with the proper reasons for whatever partial ommissions may exist: such as the data had not yet been collected for the remaining patients or whatever the reason was. A festering question is not a good thing for new investors who have not yet built up confidence in PL and team. Always better to clear the air when possible. B&B may in fact be in league with the short interests (or not), but in any case the points they raise should not be left in the air as I am confident that PLI has good responses to all those popints raised by B&B.

Glta,
Stockman6767
Bullboard Posts